Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
May 17th 2023Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
Read More